Bleomycin

colony stimulating factor 3 ; Homo sapiens







14 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 28943331 Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. 2017 Sep 4 3
2 29340124 The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD. 2017 Oct 1 1
3 23597142 Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis. 2014 Jan 1
4 22296221 Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. 2012 May 3
5 22442961 [Effects of granulocyte colony-stimulating factor on experimental bleomycin-induced pulmonary fibrosis]. 2012 2
6 16120623 Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. 2005 Sep 1
7 12771616 Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. 2003 May 1
8 12844025 [Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration]. 2003 Apr 1
9 11378548 Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. 2001 Apr 1
10 10229865 Bleomycin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. 1999 May 15 1
11 10362718 Bleomycin stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activities. 1999 Jun 1
12 9118704 Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. 1997 Mar 2
13 7513778 Possible toxicity with the association of G-CSF and bleomycin. 1994 May 14 1
14 7524599 Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. 1994 Nov 1